

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model  
Run on: February 22, 2005, 14:26:20 ; Search time 0.001 Seconds  
(without alignments)  
521.597 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTMLVTAAALLGLLMMVV.....PTLQAPRGRASEPKHKTRQR 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5  
Searched: 11 seqs, 2339 residues  
Word size : 0

Total number of hits satisfying chosen parameters: 11

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Listing first 11 summaries

Database : k035rago:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1196	99.3	223	ADI34902	Cardiovascular dis
2	1181	98.1	227	AAV94263	Human phospholipid
3	1181	98.1	227	ADSB8899	Human Phospholipid
4	1181	98.1	227	ADK70502	Respiratory disease
5	1177	97.8	227	AAV35976	Extended human sec
6	1177	97.8	227	AAV64647	Human phosphatidyl
7	1177	97.8	227	AAB88590	Human hydrophobic
8	1173	97.4	227	ADI34900	Cardiovascular dis
9	1087	90.3	201	ADI34903	Cardiovascular dis
10	1084	88.4	205	ADI34901	Cardiovascular dis
11	652	54.2	121	AAV11860	Human 5' EST seque

ALIGNMENTS

RESULT.1	
ADI34902	
ID	ADI34902 standard; protein; 223 AA.
XX	
AC	ADI34902;
XX	
DT	06-MAY-2004 (first entry)
XX	
DE	Cardiovascular disorder plasma polypeptide (CPP) 11 precursor sequence.
XX	
KW	CPP; CP10; CP11; CAD; cardiovascular disorder plasma polypeptide;
KW	cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;
XX	cardiovascular disorder; coronary artery disease; human.
OS	Homo sapiens.
XX	
Key	Location/Qualifiers

FT	Peptide	1..22
FT	Protein	/note= "signal peptide"
FT	Disulfide-bond	23..223
FT	Disulfide-bond	/note= "mature protein"
FT	Disulfide-bond	30..58
FT	Disulfide-bond	/note = disulphide bridge
FT	Disulfide-bond	43..64
FT	Disulfide-bond	/note = disulphide bridge
PN	WO2004005931-A1.	
XX	15-JAN-2004.	
XX	26-JUN-2003; 2003WO-EP006766.	
PR	08-JUL-2002; 2002US-0394576P.	
PR	07-JAN-2003; 2003US-0438664P.	
XX	(GENE-) GENEPROT INC.	
PI	Bougueleret L, Jeandenans C, Pardo B;	
XX	WPI; 2004-108914/11.	
DR	SWISSPROT; Q8WW74.	
XX	Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful for useful for screening and/or diagnosis of, or predicting cardiovascular disorder, or for identifying CPP modulator.	
PS	Claim 7; SEQ ID NO 3; 109pp; English.	
XX	Thye invention relates to isolated cardiovascular disorder plasma polypeptide (CPP), especially CP10 and CP11 and tryptic peptides derived from them. The CPP fragments are useful for screening and/or diagnosis of, or predicting a cardiovascular disorder (e.g., coronary artery disease (CAD)) in a subject. An anti-cpp antibody is useful for treating cardiovascular disorders e.g., coronary artery disease, stroke, atherosclerosis, hypertension, etc. The present sequence represents a human CP11 precursor protein sequence.	
CC	Query Match	99.3%; Score 1196; DB 1; Length 223;
CC	Best Local Similarity	99.1%; Pred. No. 0;
CC	Matches	221; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY	1	MGWTMLVTAAALLGLLMMVVVTGDEDNENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
Db	1	MGWTMLVTAAALLGLLMMVVVTGDEDNENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
QY	61	VPCNNYRQKITSWMEPIVKFPGAVDGTATILVMVDPDAPSRAPRORFWRHVLVTDIKG 120
Db	61	VPCNNYRQKITSWMEPIVKFPGAVDGTATILVMVDPDAPSRAPRORFWRHVLVTDIKG 120
QY	121	ADLKKGIQOELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180
Db	121	ADLKKGIQOELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180
QY	181	LNRFHLGEPASQTFMTQNTQDSPTLQAPRGRASEPKHKTRQR 223
Db	181	LNRFHLGEPASQTFMTQNTQDSPTLQAPRGRASEPKHKTRRR 223
RESULT 2		
AAV94263		
ID	AAV94263 standard; protein; 227 AA.	
XX		
AC	AAV94263;	
XX		
DT	01-AUG-2000 (first entry)	
XX		
DS	Human phospholipid binding protein 2, PLBP2.	
XX		

***This Page Blank (uspto)***

Human; phospholipid binding protein; PLBP2; foetal development disorder; reproduction disorder; cell proliferation disorder; immune response; autoimmune disorder; AIDS; infertility; cytostatic; immunosuppressive; gene therapy; hereditary neuropathy; phosphatidylethanolamine binding protein D1; PE-BP D1.

Homo sapiens.

Key Location/Qualifiers  
 Peptide 1..21  
 /label= signal\_peptide  
 Modified-site 4  
 /note= "Thr can be phosphorylated by protein kinase C"  
 Modified-site 21  
 /note= "Thr can be phosphorylated by casein kinase II"  
 Modified-site 67  
 /note= "Tyr can be phosphorylated by tyrosine kinase"  
 Modified-site 73  
 /note= "Ser can be phosphorylated by casein kinase II"  
 Modified-site 101  
 /note= "Ser can be phosphorylated by casein kinase II"  
 Modified-site 169  
 /note= "Aen can be glycosylated"  
 Modified-site 174  
 /note= "Ser can be phosphorylated by protein kinase C"

US6063767-A:

16-MAY-2000.

09-DEC-1998; 98US-00208718.

28-OCT-1997; 97US-00958820.

(INCY-) INCYTE PHARM INC.

Corley NC, Shah P, Lal P, Hillman JL;

WPI; 2000-375529/32.

N-PSDB; AAA15582.

New purified phospholipid binding proteins 1 and 2 useful for diagnosing, treating or preventing diseases disorders associated with fetal development, reproduction, cell proliferation, and the immune response.

Disclosure; Fig 2; 37pp; English.

The present sequence is the phospholipid binding protein 2 (PLBP2). This protein is expressed in lung, prostate and heart tissues. Also, this protein is expressed in foetal tumour tissues. PLBP2 may be used for the diagnosis, prevention, or treatment of disorders associated with foetal development (e.g. hereditary neuropathies), reproduction (e.g. infertility), cell proliferation (e.g. cancers), and the immune response (AIDS). PLBP2 antibodies may also be developed for potential drug screening or to quantitate PLBP2 gene expression in biopsied tissues. The PLBP2 gene may be administered for gene therapy of disorders associated with PLBP2. PLBP2 has high homology with the phosphatidylethanolamine binding protein D1, PE-BP D1, of *Onchocerca volvulus*. PE-BP D1 is thought to play a role in transport or signal mechanisms between membranes and the cytoplasm

Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

1 MGTWRLVTAALLGLMMVVTGDENSPCAHEALDEDTLFCQGLEVFYPPLGNIGCKV 60

1 MGTWRLVTAALLGLMMVVTGDENSPCAHEALDEDTLFCQGLEVFYPPLGNIGCKV 60

61 VPDCCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPSAEPRQRFWRHLVTDIKG 120

|||||

Db 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
 QY 121 ADLKKGKIQGQELSAYQAPSPAHSGFPHRYQFFVYLQSGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKKGKIQGQELSAYQAPSPAHSGFPHRYQFFVYLQSGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRGRASEPDKHTR 221  
 Db 181 LNRFLHGEPEASTQFMTQNYQDSPTLQAPRGRASEPDKHTR 221

RESULT 3

ADB88999

ID ADB88999 standard; protein; 227 AA.

AC ADB88999;

DT 18-DEC-2003 (first entry)

XX Human Phospholipid binding protein, PLBP2.

XX Phospholipid binding protein; PLBP2; human; membrane biogenesis;

XX foetal development; reproduction; cell proliferation; immune response;

XX Cushing's syndrome; spina bifida; epilepsy; infertility; endometriosis;

XX polycystic ovary syndrome; cancer; leukaemia; lymphoma; AIDS;

XX acquired immunodeficiency syndrome; atherosclerosis; asthma;

XX INCYTE 3126479.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 111

FT /note= "Encoded by AGC"

FT Misc-difference 131

FT /note= "Encoded by CAC"

XX US2003119730-A1.

XX 26-JUN-2003.

XX 11-JUN-2001; 2001US-00879401.

XX 28-OCT-1997; 97US-00958820.

XX 09-DEC-1998; 98US-00208718.

XX 03-SEP-1999; 99US-00390126.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Hillman JL, Corley NC, Shah P;

XX WPI; 2003-863442/80.

XX N-PSDB; ADB89000.

XX New human phospholipid binding proteins (PLBP) and polynucleotides, useful for diagnosing, preventing or treating diseases or conditions associated with aberrant PLBP expression, e.g. cancer, hepatitis, AIDS or atherosclerosis.

XX Claim 1; Fig 2; 42pp; English.

XX The invention relates to an isolated polypeptide consisting of human phospholipid binding proteins, PLBP1 and PLBP2 (ADB88997 and ADB88999), proteins involved in membrane biogenesis. Also include are their encoding polynucleotides, recombinant polynucleotides, transformed host cells (producing the proteins), an anti-PLBP antibody (or fragment), probes for detecting the polynucleotides, diagnosis/treatment of a PLBP-associated disease, screening for ant/agonists of PLBP and screening for compounds which increase/decrease PLBP expression. The probes are used to detect the polynucleotides. The antibodies are used to detect and purify the polypeptides. The PLBP proteins, polynucleotides, antibodies and isolated compounds are used to diagnose and treat diseases associated with foetal development, reproduction, cell proliferation and the immune response, e.g. Cushing's syndrome, spina bifida, epilepsy, infertility,

**This Page Blank (uspto)**

CC endometriosis, polycystic ovary syndrome, cancer, leukaemia, lymphoma,  
 CC AIDS (acquired immunodeficiency syndrome), atherosclerosis and asthma  
 CC (many more examples of these diseases are shown in the specification).  
 CC The present sequence represents human PLEB1.

XX Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 Db 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60

Qy 61 VPCNNYRQKITSWMEPIVKPFGAVDGTATYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120  
 Db 61 VPCNNYRQKITSWMEPIVKPFGAVDGTATYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120

Qy 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180

Qy 181 LNRFHLSPEASTQMTQNYQDSPTLQAPRGRASEPKHKTR 221  
 Db 181 LNRFHLSPEASTQMTQNYQDSPTLQAPRGRASEPKHKQ 221

#### RESULT 4

ADK70502  
 ID ADK70502 standard; protein; 227 AA.

XX AC ADK70502;

XX DT 06-MAY-2004 (first entry)

XX DE Respiratory disease differentially expressed protein #68.

XX DE cytostatic; respiratory; antiasthmatic; gene therapy;

XX DE differential gene expression; respiratory disorder; lung cancer;

XX DE chronic obstructive pulmonary disease; emphysema; asthma.

XX OS Homo sapiens.

XX PN WO2003101283-A2.

XX PD 11-DEC-2003.

XX PF 02-JUN-2003; 2003WO-US017409.

XX PR 04-JUN-2002; 2002US-0386005P.

XX PA (INCY-) INCYTE CORP.

XX PI Rickert PK, Krasnow R;

XX PS WPI; 2004-042945/04.

XX PT New combination comprising cDNAs and proteins that are differentially  
 expressed in respiratory disorders, useful for diagnosing or treating  
 respiratory diseases e.g. lung cancer, chronic obstructive pulmonary  
 diseases or asthma.

XX PS Claim 14; SEQ ID NO 238; 343pp; English.

XX CC The invention relates to cDNA sequences that are differentially expressed  
 in respiratory disorders or their complements or encoded proteins. The  
 cDNAs and proteins are useful for diagnosing, treating or monitoring  
 treatment of a subject with a respiratory disease including lung cancer,  
 chronic obstructive pulmonary diseases, emphysema or asthma. The protein  
 is also useful for screening molecules or compounds to identify at least  
 one ligand which specifically binds the protein. It is also useful for  
 preparing and purifying a polyclonal or monoclonal antibody. This

CC sequence corresponds to a protein of the invention.

XX Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 Db 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60

Qy 61 VPCNNYRQKITSWMEPIVKPFGAVDGTATYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120  
 Db 61 VPCNNYRQKITSWMEPIVKPFGAVDGTATYILVMVDPDAPSRAPRQRFWRHMLVTDIKG 120

Qy 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 Db 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180

Qy 181 LNRFHLSPEASTQMTQNYQDSPTLQAPRGRASEPKHKTR 221  
 Db 181 LNRFHLSPEASTQMTQNYQDSPTLQAPRGRASEPKHKQ 221

#### RESULT 5

AAV35976

ID AAV35976 standard; protein; 227 AA.

XX AC AAV35976;

XX DT 13-SEP-1999 (first entry)

XX DE Extended human secreted protein sequence, SEQ ID NO. 225.

XX DE Secreted protein; human; cytokine; cellular proliferation; cell movement;  
 cellular differentiation; immune system regulator; anti-inflammatory;  
 haematopoiesis regulator; tissue growth regulator; tumour inhibitor;  
 reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;  
 genetic disease.

XX OS Homo sapiens.

XX PN WO9931236-A2.

XX PD 24-JUN-1999.

XX PF 17-DEC-1998; 98WO-18002122.

XX PR 17-DEC-1997; 97US-0069957P.

XX PR 03-FEB-1998; 98US-0074121P.

XX PR 13-APR-1998; 98US-0081563P.

XX PR 10-AUG-1998; 98US-0096116P.

XX PA (GEST ) GENSET.

XX PI Bougueleret L, Duclert A, Dumas Milne Edwards J;

XX PS WPI; 1999-385906/32.

XX PT New isolated human secreted proteins.

XX PS Claim 9; Page 255; 516pp; English.

XX CC This sequence is encoded by an extended human secreted protein coding  
 sequence of the invention. The secreted proteins can be used in treating  
 or controlling a variety of human conditions. The secreted proteins may  
 act as cytokines or may affect cellular proliferation or differentiation  
 or may act as immune system regulators, haematopoiesis regulators, tissue  
 growth regulators, regulators of reproductive hormones or cell movement  
 or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or  
 tumour inhibition activity. The DNAs can be used in forensic procedures

This Page Blank (uspto)

CC to identify individuals or in diagnostic procedures to identify  
 CC individuals having genetic diseases resulting from abnormal expression of  
 CC the genes corresponding to the extended cDNAs. They are also useful for  
 CC constructing a high resolution map of the human chromosomes. They can  
 CC also be used for gene therapy to control or treat genetic diseases  
 XX  
 SQ Sequence 227 AA;

Query Match 97.8%; Score 1177; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 MGWTLRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPPELGNIGCKV 60  
 DB 1 MGWTLRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPPELGNIGCKV 60  
 QY 61 VPCDNNYRQKITSWMEPIVKFPGAVDGYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
 DB 61 VPCDNNYRQKITSWMEPIVKFPGAVDGYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
 QY 121 ADLKGKIKQOELSAVOAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIKQOELSAVOAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFTONTQYQDSPTLOAPRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFTONTQYQDSPTLOAPRASEPKHKTR 221

RESULT 6  
 AAY64647  
 ID AAY64647 standard; protein; 227 AA.  
 XX  
 AC AAY64647;  
 XX  
 DT 01-FEB-2000 (first entry)  
 XX  
 DE Human phosphatidylethanolamine-binding protein.  
 XX  
 KW Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;  
 KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;  
 KW location; development; protein synthesis; stability; regulation;  
 KW identification.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO9553051-A2.  
 XX  
 PD 21-OCT-1999.  
 XX  
 PF 09-APR-1999; 99WO-IB000712.  
 XX  
 PR 09-APR-1998; 98US-00057719.  
 PR 28-APR-1998; 98US-00069047.  
 XX  
 PA (GEST ) GENSET.  
 XX  
 PI Dumas Milne Edwards, Duclert A, Giordano J;  
 XX  
 DR WPI; 2000-038446/03.  
 DR N-PSDB; AA242252.  
 XX

Novel secreted protein 5' expressed sequence tag sequences used in  
 PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.  
 PT  
 XX Example 21; Page 169-170; 837pp; English.  
 XX  
 CC AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)  
 CC sequences, corresponding to human secreted proteins. AAY64651 to AAY65438  
 CC represent the EST-related proteins corresponding to AA242265 to AA243052.  
 CC The 5' ESTs can be used for producing secreted human gene products. They  
 CC can be used to identify and isolate 5' untranslated regions (UTRs) and  
 CC upstream regulatory regions which control the location, development

CC stage, rate, and quantity of protein synthesis, as well as stability of  
 CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to  
 CC obtain full length cDNA clones. The ESTs can also be used in forensic  
 CC procedures to identify individuals, or in diagnostic procedures to  
 CC identify individuals having genetic diseases resulting from abnormal gene  
 CC expression. The products may also be used in gene therapy protocols. The  
 CC nucleic acids encoding signal peptides can be used for directing  
 CC polypeptide into a membrane, or importing a polypeptide into a cell. The  
 CC proteins encoded by the EST sequences may be useful in treating a variety  
 CC of human conditions. Secreted proteins have therapeutic value, and the  
 CC identification of new secreted proteins is valuable. AA242249 to AA242264  
 CC and AAY64644 to AAY64650 represent sequences used in the exemplification  
 CC of the present invention  
 XX  
 SQ Sequence 227 AA;

Query Match 97.8%; Score 1177; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 MGWTLRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPPELGNIGCKV 60  
 DB 1 MGWTLRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYPPELGNIGCKV 60  
 QY 61 VPCDNNYRQKITSWMEPIVKFPGAVDGYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
 DB 61 VPCDNNYRQKITSWMEPIVKFPGAVDGYILVMVDPDAPSPRAEPQRFWRHLVTDIKG 120  
 QY 121 ADLKGKIKQOELSAVOAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIKQOELSAVOAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFTONTQYQDSPTLOAPRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFTONTQYQDSPTLOAPRASEPKHKTR 221

RESULT 7  
 AAB88590  
 ID AAB88590 standard; protein; 227 AA.  
 XX  
 AC AAB88590;  
 XX  
 DT 04-JUN-2001 (first entry)  
 XX  
 DE Human hydrophobic domain containing protein clone HP03880 #94.  
 XX  
 KW Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;  
 KW antianemic; vulnery; antitumor; osteopathic; anti-inflammatory;  
 KW cytostatic; gene therapy; autoimmune disorder; multiple sclerosis;  
 KW HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;  
 KW inflammatory bowel disease; nutritional supplement; appetite; vaccine;  
 KW behavioural characteristic; immune response.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200112660-A2.  
 XX  
 PD 22-FEB-2001.  
 XX  
 PF 10-AUG-2000; 2000WO-JP005356.  
 XX  
 PR 17-AUG-1999; 99JP-00230344.  
 PR 07-SEP-1999; 99JP-00252551.  
 PR 01-OCT-1999; 99JP-00281132.  
 PR 22-OCT-1999; 99JP-00301624.  
 PR 04-NOV-1999; 99JP-00313877.  
 XX  
 PA (SAGA ) SAGAMI CHEM RES CENT.  
 PA (PROT-) PROTEGENE INC.  
 XX  
 PI Kato S, Kimura T;

This Page Blank (uspto)



GenCore version 5.1.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 22, 2005, 14:27:54 ; Search time 1 Seconds  
(without alignments)  
0.051 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTNRLVTAALLGLMMVV.....PTLQAPGRASEPKHKTRQ 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1 seqs, 227 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Listing first 1 summaries

Database : k035rapbo.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1171	97.3	227	1	US-09-895-298-107
					Sequence 107, App

ALIGNMENTS

RESULT 1  
US-09-895-298-107  
; Sequence 107, Application US/09895298  
; Publication No. US20030078405A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: 47 Human Secreted Proteins  
; FILE REFERENCE: P2035P1  
; CURRENT APPLICATION NUMBER: US/09/895,298  
; PRIOR FILING DATE: 2001-07-02  
; PRIOR APPLICATION NUMBER: 09/591,16  
; PRIOR FILING DATE: 2000-06-09  
; PRIOR APPLICATION NUMBER: PCT/US99/29950  
; PRIOR FILING DATE: 1999-12-16  
; PRIOR APPLICATION NUMBER: 60/113,006  
; PRIOR FILING DATE: 1998-12-18  
; PRIOR APPLICATION NUMBER: 60/112,809  
; PRIOR FILING DATE: 1998-12-17  
; NUMBER OF SEQ ID NOS: 231  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 107  
; LENGTH: 227  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (125)

OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-895-298-107

Query Match 97.3%; Score 1171; DB 1; Length 227;  
Best Local Similarity 98.2%; Pred. No. 0;  
Matches 217; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 MGWTNRLVTAALLGLMMVVTTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
DB 1 MGWTNRLVTAALLGLMMVVTTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYTILVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYTILVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
QY 121 ADLKKGKIQQOELSAIQAPSPPAHSGFHRYPFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
DB 121 ADLKKGKIQQOELSAIQAPSPPAHSGFHRYPFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
QY 181 LNRPHLGEPEASTQFMTQNYQDSPTLQAPGRASEPKHKTR 221  
DB 181 LNRPHLGEPEASTQFMTQNYQDSPTLQAPGRASEPKHKNQ 221

Search completed: February 22, 2005, 14:27:55  
Job time : 1 secs

...is Page Blank (uspto)

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM protein - protein search, using sw model  
Run on: February 22, 2005, 12:59:09 ; Search time 0.001 Seconds  
(without alignments)  
101.242 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTMRLVTAALLGLMMVV.....PTLQAPGRASEPKHKTRQR 223

Scoring table:  
BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2 seqs, 454 residues  
Total number of hits satisfying chosen parameters: 2

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 2 summaries  
Database : k035rapb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	ID	Description
1	1181	98.1	227	1 US-09-879-401-3	Sequence 3, Appli
2	1173	97.4	227	1 US-10-003-152-2	Sequence 2, Appli

ALIGNMENTS

RESULT 1  
US-09-879-401-3  
; Sequence 3, Application US/09879401  
; Publication No. US20030119730A1  
; GENERAL INFORMATION:  
; APPLICANT: Lal, Preeti  
; Hillman, Jennifer  
; Corley, Neil  
; Shah, Purvi  
; TITLE OF INVENTION: HUMAN PHOSPHOLIPID BINDING PROTEINS  
; NUMBER OF SEQUENCES: 6  
; CORRESPONDENCE ADDRESS:  
; ADDRESS: Incyte Pharmaceuticals, Inc.  
; STREET: 3174 Porter Dr.  
; CITY: Palo Alto  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94304  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/879,401  
; FILING DATE: 11-Jun-2001

CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/958,820  
FILING DATE: <Unknown>  
ATTORNEY/AGENT INFORMATION:  
NAME: Billings, Lucy J.  
REGISTRATION NUMBER: 36,749  
REFERENCE/DOCKET NUMBER: PF-0379 US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 650-855-0555  
TELEFAX: 650-845-4166  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 227 amino acids  
TYPE: amino acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
LIBRARY: LUNGUT12  
CLONE: 3126479  
SEQUENCE DESCRIPTION: SEQ ID NO: 3:  
US-09-879-401-3  
Query Match 98.1%; Score 1181; DB 1; Length 227;  
Best Local Similarity 98.6%; Pred. No. 0;  
Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MGWTMRLVTAALLGLMMVVTDGDEDENSPCAHEALLDSDTLFCQGLEVFYFPELGNIGCKV 60  
DB 1 MGWTMRLVTAALLGLMMVVTDGDEDENSPCAHEALLDSDTLFCQGLEVFYFPELGNIGCKV 60  
QY 61 VPDCCNYRQKITSWMEPIVKFPGAVDGYATYLLVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
DB 61 VPDCCNYRQKITSWMEPIVKFPGAVDGYATYLLVMVDPDAPSAEPRQRFWRHLVTDIKG 120  
QY 121 ADLKKGIQGOELSAQAPSPPAHSGFHYOFFFVYLOEGKVISLLPKENKTRGSGWMDRF 180  
DB 121 ADLKEGKIQGOELSAQAPSPPAHSGFHYOFFFVYLOEGKVISLLPKENKTRGSGWMDRF 180  
QY 181 LNRHFLGPEASTQPMNTQNYQDSPTLQAPGRASEPKHKTR 221  
DB 181 LNRHFLGPEASTQPMNTQNYQDSPTLQAPGRASEPKHKQ 221

RESULT 2  
US-10-003-152-2  
; Sequence 2, Application US/10003152  
; Publication No. US20020151494A1  
; GENERAL INFORMATION:  
; APPLICANT: Shimkets, Richard  
; APPLICANT: Fernandes, Elma  
; APPLICANT: Vernet, Corine  
; APPLICANT: Yang, Meijia  
; APPLICANT: Boldog, Ferenc  
; APPLICANT: Herrmann, John  
; TITLE OF INVENTION: No. US20020151494A1el Amino Acid Sequences for Human Semaphorin-1  
; FILE REFERENCE: 15966-554 Cura-54 CON-S12  
; CURRENT APPLICATION NUMBER: US/10/003,152  
; CURRENT FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 09/604,286  
; PRIOR FILING DATE: 2000-06-22  
; PRIOR APPLICATION NUMBER: 60/140,584  
; PRIOR FILING DATE: 1999-06-23  
; NUMBER OF SEQ ID NOS: 49  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 2  
; LENGTH: 227  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-003-152-2  
Query Match 97.4%; Score 1173; DB 1; Length 227;  
Best Local Similarity 98.2%; Pred. No. 0;

Tue Feb 22 13:08:20 2005

Matches 217;		Conservative	2;	Mismatches	2;	Indels	0;	Gaps	0;
Qy	1	MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV	60						
Db	1	MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV	60						
Qy	61	VPDCNNYRQKITSWMEPIVKPFGAVDGYIILVMVDPDAPSRABPRQRFWRHNLVTDIKG	120						
Db	61	VPDCNNYRQKITSWMEPIVKPFGAVDGYIILVMVDPDAPSRABPRQRFWRHNLVTDIKG	120						
Qy	121	ADLKGKIQGQELSAQAPSPPAHSGFHRQYQFFVYLQEGKVISLLPKENKTRGSKMDRF	180						
Db	121	ADLKGKIQGQELSAQAPSPPAHSGFHRQYQFFVYLQEGKVISLLPKENKTRGSKMDRF	180						
Qy	181	LNRFLGPEPEASTQFMTONYQDSPTLOAPRASEPKHKTR	221						
Db	181	LNRFLGPEPEASTQFMTONYQDSPTLOAPRASEPKHKQ	221						

Search completed: February 22, 2005, 12:59:09  
Job time : 0.001 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM protein - protein search, using sw model  
Run on: February 22, 2005, 12:54:10 ; Search time 0.001 Seconds  
(without alignments)  
612.135 Million cell updates/sec

Title: US-10-035-958-61  
Perfect score: 1204  
Sequence: 1 MGWTRLVTAALLGLMMVV.....PTLQAPGRASEPKHKTROR 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5  
Searched: 13 seqs, 2745 residues

Total number of hits satisfying chosen parameters: 13  
Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 13 summaries

Database : kol035rag:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1200	99.7	223	AAU14138	Human novel protei
2	1196	99.3	223	ADI34902	Cardiovascular dis
3	1181	98.1	227	AAV94263	Human phospholipid
4	1181	98.1	227	AD888999	Human Phospholipid
5	1181	98.1	227	ADK70502	Respiratory disease
6	1177	97.8	227	AAV35976	Extended human sec
7	1177	97.8	227	AAV64647	Human phosphatidyl
8	1177	97.8	227	AA888590	Human hydrophobic
9	1173	97.4	227	ADI34900	Cardiovascular dis
10	1087	90.3	201	ADI34903	Cardiovascular dis
11	1064	88.4	205	ADI34901	Cardiovascular dis
12	743.5	61.8	183	ADH80692	Human polypeptide
13	652	54.2	121	AAV11860	Human 5' EST seque

ALIGNMENTS

RESULT 1  
AAU14138  
ID AAU14138 standard; protein; 223 AA.  
XX  
AC AAU14138;  
XX  
DT 24-OCT-2001 (first entry)  
XX  
XX Human novel protein #9.  
DE  
XX Human; novel protein; Antianaemic; osteopathic; antiinflammatory;  
KW immunomodulatory; cytoskeletal; neuroprotective; vulnerrary; nootropic;  
KW anticonvulsant; antiarthritic; cerebroprotective; antifungal; antiviral;  
KW antibacterial; antiallergic; dermatological; haemostatic; antiasthmatic;  
KW thrombolytic; immunogen; antibody; gene therapy; neurological disorder;

KW Parkinson's disease; inflammatory disorder; cancer; asthma; osteoporosis;  
XX tissue regeneration; immune disorder.  
OS Homo sapiens.  
XX WO200155437-A2.  
XX  
PD 02-AUG-2001.  
XX  
XX 25-JAN-2001; 2001WO-US002623.  
XX PF  
XX 25-JAN-2000; 2000US-00491404.  
XX PR  
XX (HYSE-) HYSEQ INC.  
XX PA  
XX Tang YT, Liu C, Drmanac RT;  
XX WPI; 2001-451939/48.  
XX DR N-PSDB; AAS22443.  
XX  
XX Isolated polypeptides useful for treating anti-inflammatory diseases,  
PT nervous system disorders, and for regenerating bone and cartilage.  
XX  
XX Example 4; Page 528-529; 894pp; English.  
XX  
XX The invention relates to polynucleotides encoding novel human proteins or  
CC their active domains. The polypeptides, polynucleotides and antibodies  
CC raised against the polypeptides are used in a method of treatment of a  
CC mammal and prevention of disorders caused by the aberrant protein  
CC expression or activity. The polypeptides can be used as molecular weight  
CC markers, food supplements, and in antibody production. The polypeptides  
CC are used to identify compounds which bind to the polypeptides.  
CC Polynucleotides of the invention are used as probes and primers, for  
CC sequencing, for chromosome or gene mapping, in the production of  
CC recombinant proteins, and in generating anti-sense DNA or RNA and in gene  
CC therapy. Polypeptides of the invention can be used to target drugs to a  
CC tumour, in assays to determine biological activity, to raise  
CC antibodies/elicit an immune response, to determine quantitative protein  
CC levels, as tissue markers, and to isolate receptors or ligands.  
CC Polypeptides of the invention may also be useful in treating platelet  
CC disorders, stem cell disorders, regenerating bone, cartilage, tendon,  
CC ligament and/or nerve tissue, wound healing, treating burns, promoting  
CC the proliferation, differentiation and survival of stem cells, as a  
CC contraceptive, treating osteoporosis and osteoarthritis, anaemia,  
CC Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral  
CC sclerosis, stroke, immune deficiencies resulting from bacterial, viral or  
CC fungal infection or from autoimmunity, cancer, allergy, asthma, graft-  
CC versus-host disease, eczema, haemophilia, thrombosis, anti-inflammatory  
CC diseases, nervous system disorders, and infection. The present sequence  
CC represents a protein of the invention  
SQ Sequence 223 AA;

Query Match 99.7%; Score 1200; DB 1; Length 223;  
Best Local Similarity 99.6%; Pred. No. 0;  
Matches 222; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MGWTRLVTAALLGLMMVVTDGDENSPCAHEALLDEDTLFCQGLEVFYPGLNIGCKV 60  
Db 1 MGWTRLVTAALLGLMMVVTDGDENSPCAHEALLDEDTLFCQGLEVFYPGLNIGCKV 60  
QY 61 VPDCCNNYRQKITSWMPEIVKFPFAGVDGATYILVMVDPDAPSAEPQRQFRHVLVTDIKG 120  
Db 61 VPDCCNNYRQKITSWMPEIVKFPFAGVDGATYILVMVDPDAPSAEPQRQFRHVLVTDIKG 120  
QY 121 ADLKGKIQGQELSAYQAPSPAHSGFHYQFFVYLQEGKVLSLIPKENTKRGSKWMDRF 180  
Db 121 ADLKGKIQGQELSAYQAPSPAHSGFHYQFFVYLQEGKVLSLIPKENTKRGSKWMDRF 180  
QY 181 LNRPHLGEPEASTQMTQNYQDSPTLQAPGRASEPKHKTROR 223  
Db 181 LNRPHLGEPEASTQMTQNYQDSPTLQAPGRASEPKHKTROR 223

```
RESULT 2
ADI34902
ID ADI34902 standard; protein; 223 AA.
XX AC ADI34902;
XX DT 06-MAY-2004 (first entry)
XX DE Cardiovascular disorder plasma polypeptide (CPP) 11 precursor sequence.
XX KW CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;
KW cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;
KW cardiovascular disorder; coronary artery disease; human.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Peptide 1..22
XX FT Protein /note= "signal peptide"
XX FT Disulfide-bond 30..58 /note= "mature protein"
XX FT Disulfide-bond 43..64 /note = disulphide bridge
XX FT Disulfide-bond 43..64 /note = disulphide bridge
XX PN WO2004005931-A1.
XX PD 15-JAN-2004.
XX PF 26-JUN-2003; 2003WO-EP006766.
XX PR 08-JUL-2002; 2002US-0394576P.
XX PR 07-JAN-2003; 2003US-0438664P.
XX PA (GENE-) GENEPROT INC.
XX PI Bougueleret L, Jeandenans C, Pardo B;
XX WPI: 2004-108914/11.
XX SWISSPROT; Q8WV74.
XX PT Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful
PT for useful for screening and/or diagnosis of, or predicting
PT cardiovascular disorder, or for identifying CPP modulator.
XX PS Claim 7; SEQ ID NO 3; 109pp; English.
XX CC Thye invention relates to isolated cardiovascular disorder plasma
CC polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides
CC derived from them. The CPP fragments are useful for screening and/or
CC diagnosis of, or predicting a cardiovascular disorder (e.g., coronary
CC artery disease (CAD)) in a subject. An anti-CPP antibody is useful for
CC treating cardiovascular disorders e.g., coronary artery disease, stroke,
CC atherosclerosis, hypertension, etc. The present sequence represents a
CC human CPP11 precursor protein sequence.
XX SQ Sequence 223 AA;
Query Match 99.3%; Score 1196; DB 1; Length 223;
Best Local Similarity 99.1%; Pred. No. 0;
Matches 221; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1 MGMTWRLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
DB 1 MGMTWRLVTAALLGLMMVVTGDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60
QY 61 VPDCCNRYRKITSWMEPIVKFFGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
DB 61 VPDCCNRYRKITSWMEPIVKFFGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
QY 121 ADLKKGKIQQGELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSWKMDRF 180
```

```
Db 121 ADLKKGKIQQGELSAYQAPSPPAHSGFHYQFFVYLOEGKVISLLPKENKTRGSWKMDRF 180
QY 181 LNRFHLGEPEASTQMTQNYQDSPTLQAPRGRASEPKHKTROR 223
DB 181 LNRFHLGEPEASTQMTQNYQDSPTLQAPRGRASEPKHKTRRR 223

RESULT 3
AAY94263
ID AAY94263 standard; protein; 227 AA.
XX AC AAY94263;
XX DT 01-AUG-2000 (first entry)
XX DE Human phospholipid binding protein 2, PLBP2.
XX KW Human, phospholipid binding protein; PLBP2; foetal development disorder;
KW reproduction disorder; cell proliferation disorder; immune response;
KW autoimmune disorder; AIDS; infertility; cytostatic; immunosuppressive;
KW gene therapy; hereditary neuropathy;
KW phosphatidylethanolamine binding protein D1; PE-BP D1.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT Peptide 1..21
XX FT Modified-site 4 /label= signal_peptide
XX FT Modified-site 21 /note= "Thr can be phosphorylated by protein kinase C"
XX FT Modified-site 67 /note= "Thr can be phosphorylated by casein kinase II"
XX FT Modified-site 73 /note= "Tyr can be phosphorylated by tyrosine kinase"
XX FT Modified-site 101 /note= "Ser can be phosphorylated by casein kinase II"
XX FT Modified-site 169 /note= "Ser can be phosphorylated by casein kinase II"
XX FT Modified-site 174 /note= "Asn can be glycosylated"
XX FT Modified-site /note= "Ser can be phosphorylated by protein kinase C"
XX PN US6063767-A.
XX PD 16-MAY-2000.
XX PF 09-DEC-1998; 98US-00208718.
XX PR 28-OCT-1997; 97US-00958820.
XX PA (INCY-) INCYTE PHARM INC.
XX PI Corley NC, Shah P, Lal P, Hillman JL;
XX WPI: 2000-375529/32.
XX N-PSDB; AAA15582.
XX PT New purified phospholipid binding proteins 1 and 2 useful for diagnosing,
PT treating or preventing diseases disorders associated with fetal
PT development, reproduction, cell proliferation, and the immune response.
XX PS Disclosure; Fig 2; 37pp; English.
XX CC The present sequence is the phospholipid binding protein 2 (PLBP2). This
CC protein is expressed in lung, prostate and heart tissues. Also, this
CC protein is expressed in foetal tumour tissues. PLBP2 may be used for the
CC diagnosis, prevention, or treatment of disorders associated with foetal
CC development (e.g. hereditary neuropathies), reproduction (e.g.
CC infertility), cell proliferation (e.g. cancers), and the immune response
CC (AIDS). PLBP2 antibodies may also be developed for potential drug
CC screening or to quantitate PLBP2 gene expression in biopsied tissues. The
```

CC PLBP2 gene may be administered for gene therapy of disorders associated  
 CC with PLBP2. PLBP2 has high homology with the phosphatidylethanolamine  
 CC binding protein DI, PE-BP DI, of *Onchocerca volvulus*. PE-BP DI is thought  
 CC to play a role in transport or signal mechanisms between membranes and  
 CC the cytoplasm

XX Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPLGNIGCKV 60  
 DB 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPLGNIGCKV 60  
 QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPSRAEPRQFRHMLVTDIKG 120  
 DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPSRAEPRQFRHMLVTDIKG 120  
 QY 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKNQ 221

#### RESULT 4

ADB88999  
 ID ADB88999 standard; protein; 227 AA.

AC ADB88999;

DT 18-DEC-2003 (first entry)

DE Human Phospholipid binding protein, PLBP2.

XX Phospholipid binding protein; PLBP2; human; membrane biogenesis;  
 KW foetal development; reproduction; cell proliferation; immune response;  
 KW Cushing's syndrome; spina bifida; epilepsy; infertility; endometriosis;  
 KW polycystic ovary syndrome; cancer; leukaemia; lymphoma; AIDS;  
 KW acquired immunodeficiency syndrome; atherosclerosis; asthma;  
 KW INCYTE 3126479.

XX Homo sapiens.

OS Key Location/Qualifiers

FT Misc-difference 111 /note= "Encoded by AGC"

FT Misc-difference 131 /note= "Encoded by CAC"

XX US2003119730-A1.

XX 26-JUN-2003.

XX 11-JUN-2001; 2001US-00879401.

XX 28-OCT-1997; 97US-00958820.

XX 09-DEC-1998; 98US-00208718.

XX 03-SEP-1999; 99US-00390126.

XX (INCY-) INCYTE PHARM INC.

XX Lal P, Hillman JL, Corley NC, Shah P;

XX WPI; 2003-863442/80.

XX N-PSDB; ADB89000.

XX New human phospholipid binding proteins (PLBP) and polynucleotides,

PT useful for diagnosing, preventing or treating diseases or conditions

PT associated with aberrant PLBP expression, e.g. cancer, hepatitis, AIDS or  
 PT atherosclerosis.

XX Claim 1; Fig 2; 42pp; English.

XX The invention relates to an isolated polypeptide consisting of human  
 CC phospholipid binding proteins, PLBP1 and PLBP2 (ADB88997 and ADB88999),  
 CC proteins involved in membrane biogenesis. Also include are their encoding  
 CC polynucleotides, recombinant polynucleotides, transformed host cells  
 CC (producing the proteins), an anti-PLBP antibody (or fragment), probes for  
 CC detecting the polynucleotides, diagnosis/treatment of a PLBP-associated  
 CC disease, screening for ant/agonists of PLBP and screening for compounds  
 CC which increase/decrease PLBP expression. The probes are used to detect  
 CC the polynucleotides. The antibodies are used to detect and purify the  
 CC polypeptides. The PLBP proteins, polynucleotides, antibodies and isolated  
 CC compounds are used to diagnose and treat diseases associated with foetal  
 CC development, reproduction, cell proliferation and the immune response,  
 CC e.g. Cushing's syndrome, spina bifida, epilepsy, infertility,  
 CC endometriosis, polycystic ovary syndrome, cancer, leukaemia, lymphoma,  
 CC AIDS (acquired immunodeficiency syndrome), atherosclerosis and asthma,  
 CC (many more examples of these diseases are shown in the specification).  
 CC The present sequence represents human PLBP1.

XX Sequence 227 AA;

Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPLGNIGCKV 60

DB 1 MGWTWRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPLGNIGCKV 60

QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPSRAEPRQFRHMLVTDIKG 120

DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGATYILVMVDPDAPSRAEPRQFRHMLVTDIKG 120

QY 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180

DB 121 ADLKGKIQGQELSAYQAPSPPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180

QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKTR 221

DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPGRASEPKHKNQ 221

#### RESULT 5

ADK70502

ID ADK70502 standard; protein; 227 AA.

XX AC ADK70502;

XX 06-MAY-2004 (first entry)

XX Respiratory disease differentially expressed protein #68.

XX cytostatic; respiratory; antiasthmatic; gene therapy;  
 KW differential gene expression; respiratory disorder; lung cancer;  
 KW chronic obstructive pulmonary disease; emphysema; asthma.

XX Homo sapiens.

XX WO2003101283-A2.

XX 11-DEC-2003.

XX 02-JUN-2003; 2003WO-US017409.

XX 04-JUN-2002; 2002US-0386005P.

XX (INCY-) INCYTE CORP.

XX Rickert PK, Kraenow R;

XX WPI; 2004-042945/04.  
 XX  
 DR  
 XX  
 PT New combination comprising cDNAs and proteins that are differentially  
 PT expressed in respiratory disorders, useful for diagnosing or treating  
 PT respiratory diseases e.g. lung cancer, chronic obstructive pulmonary  
 PT diseases or asthma.  
 PT  
 XX  
 PS Claim 14; SEQ ID NO 238; 343pp; English.  
 XX  
 XX The invention relates to cDNA sequences that are differentially expressed  
 CC in respiratory disorders or their complements or encoded proteins. The  
 CC cDNAs and proteins are useful for diagnosing, treating or monitoring  
 CC treatment of a subject with a respiratory disease including lung cancer,  
 CC chronic obstructive pulmonary diseases, emphysema or asthma. The protein  
 CC is also useful for screening molecules or compounds to identify at least  
 CC one ligand which specifically binds the protein. It is also useful for  
 CC preparing and purifying a polyclonal or monoclonal antibody. This  
 CC sequence corresponds to a protein of the invention.  
 XX  
 SQ Sequence 227 AA;  
 Query Match 98.1%; Score 1181; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 DB 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 QY 61 VPDCCNRYQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRFWRHVLVTDIKG 120  
 DB 61 VPDCCNRYQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRFWRHVLVTDIKG 120  
 QY 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFMNTQNYQDSPTLQAPRGRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFMNTQNYQDSPTLQAPRGRASEPKHKTR 221  
 RESULT 6  
 ID AAY35976 standard; protein; 227 AA.  
 XX AAY35976;  
 AC  
 XX  
 DT 13-SEP-1999 (first entry)  
 DE Extended human secreted protein sequence, SEQ ID NO. 225.  
 XX Secreted protein; human; cytokine; cellular proliferation; cell movement;  
 XX cellular differentiation; immune system regulator; anti-inflammatory;  
 KW haematopoiesis regulator; tissue growth regulator; tumour inhibitor;  
 KW reproductive hormone regulator; chemotaxis; chemokinesis; gene therapy;  
 XX genetic disease.  
 XX Homo sapiens.  
 OS  
 XX WO9931236-A2.  
 PN  
 XX 24-JUN-1999.  
 PD  
 XX 17-DEC-1998; 98WO-IB002122.  
 PF  
 XX 17-DEC-1997; 97US-0069957P.  
 PR 09-FEB-1998; 98US-0074121P.  
 PR 13-APR-1998; 98US-0081563P.  
 PR 10-AUG-1998; 98US-0096116P.  
 XX (GIST ) GENSET.

XX Bouqueleret L, Duclert A, Dumas Milne Edwards J;  
 PI  
 XX  
 DR WPI; 1999-385906/32.  
 DR N-FSD; AAX97660.  
 XX  
 PT New isolated human secreted proteins.  
 PT  
 XX  
 PS Claim 9; Page 255; 516pp; English.  
 XX  
 XX This sequence is encoded by an extended human secreted protein coding  
 CC sequence of the invention. The secreted proteins can be used in treating  
 CC or controlling a variety of human conditions. The secreted proteins may  
 CC act as cytokines or may affect cellular proliferation or differentiation  
 CC or may act as immune system regulators, haematopoiesis regulators, tissue  
 CC growth regulators, regulators of reproductive hormones or cell movement  
 CC or have chemotactic/chemokinetic, receptor/ligand, anti-inflammatory or  
 CC tumour inhibition activity. The DNAs can be used in forensic procedures  
 CC to identify individuals or in diagnostic procedures to identify  
 CC individuals having genetic diseases resulting from abnormal expression of  
 CC the genes corresponding to the extended cDNAs. They are also useful for  
 CC constructing a high resolution map of the human chromosomes. They can  
 CC also be used for gene therapy to control or treat genetic diseases  
 XX  
 SQ Sequence 227 AA;  
 Query Match 97.8%; Score 1177; DB 1; Length 227;  
 Best Local Similarity 98.6%; Pred. No. 0;  
 Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 DB 1 MGWTRLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
 QY 61 VPDCCNRYQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRFWRHVLVTDIKG 120  
 DB 61 VPDCCNRYQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRFWRHVLVTDIKG 120  
 QY 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 DB 121 ADLKGKIQOGLSAYQAPSPPAHSGFHRHYQFFVYLOEGKVISLLPKENKTRGSKWMDRF 180  
 QY 181 LNRFLHGEPEASTQFMNTQNYQDSPTLQAPRGRASEPKHKTR 221  
 DB 181 LNRFLHGEPEASTQFMNTQNYQDSPTLQAPRGRASEPKHKTR 221  
 RESULT 7  
 ID AAY64647 standard; protein; 227 AA.  
 XX AAY64647;  
 AC  
 XX 01-FEB-2000 (first entry)  
 DT Human phosphatidylethanolamine-binding protein.  
 XX Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;  
 KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;  
 KW location; development; protein synthesis; stability; regulation;  
 KW identification.  
 XX Homo sapiens.  
 OS  
 XX WO9953051-A2.  
 PN  
 XX 21-OCT-1999.  
 PD  
 XX 09-APR-1999; 99WO-IB000712.  
 PF  
 XX 09-APR-1998; 98US-00057719.  
 PR 28-APR-1998; 98US-00069047.  
 PR



```

PA (GEST ) GENSET.
XX
PI Dumas Milne Edwards J, Duclert A, Giordano J;
XX
XX WPI; 2000-038446/03.
XX DR N-PSDB; AA242252.
XX
PT Novel secreted protein 5' expressed sequence tag sequences used in
PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.
XX
XX Example 21; Page 169-170; 837pp; English.
XX
CC AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)
CC sequences, corresponding to human secreted proteins. AA242265 to AA242265 to AA242265
CC represent the EST-related proteins corresponding to AA242265 to AA242265.
CC The 5' ESTs can be used for producing secreted human gene products. They
CC can be used to identify and isolate 5' untranslated regions (UTRs) and
CC upstream regulatory regions which control the location, development
CC stage, rate, and quantity of protein synthesis, as well as stability of
CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to
CC obtain full length cDNA clones. The ESTs can also be used in forensic
CC procedures to identify individuals, or in diagnostic procedures to
CC identify individuals having genetic diseases resulting from abnormal gene
CC expression. The products may also be used in gene therapy protocols. The
CC nucleic acids encoding signal peptides can be used for directing
CC extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell. The
CC proteins encoded by the EST sequences may be useful in treating a variety
CC of human conditions. Secreted proteins have therapeutic value, and the
CC identification of new secreted proteins is valuable. AA242249 to AA242264
CC and AA242264 to AA242265 represent sequences used in the exemplification
CC of the present invention
XX
SQ Sequence 227 AA;
Query Match 97.8%; Score 1177; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
DB 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
QY 61 VPDCCNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
DB 61 VPDCCNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
QY 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPQFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPQFVYLQEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFTMTQYQDSPTLQAPRGRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFTMTQYQDSPTLQAPRGRASEPKHKQ 221
RESULT 8
ID AAB88590
XX AAB88590 standard; protein; 227 AA.
XX
AC AAB88590;
XX
XX 04-JUN-2001 (first entry)
XX
DE Human hydrophobic domain containing protein clone HP03880 #94.
XX
KW Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;
KW antianaemic; vulnary; antiulcer; osteopathic; anti-inflammatory;
KW cytosolic; gene therapy; autoimmune disorder; multiple sclerosis;
KW HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;
KW inflammatory bowel disease; nutritional supplement; appetite; vaccine;
KW behavioural characteristic; immune response.
XX
OS Homo sapiens.
XX
PN WO200112660-A2.
XX
XX 22-FEB-2001.
XX
XX 10-AUG-2000; 2000WO-JP005356.
XX
XX 17-AUG-1999; 99JP-00230344.
XX 07-SEP-1999; 99JP-00252551.
XX 01-OCT-1999; 99JP-00281132.
XX 22-OCT-1999; 99JP-00301624.
XX 04-NOV-1999; 99JP-00313877.
XX
XX (SAGA ) SAGAMI CHEM RES CENT.
XX (PROT-) PROTEGENE INC.
XX
XX Kato S, Kimura T;
XX
XX WPI; 2001-160059/16.
XX N-PSDB; AAF94480.
XX
XX Human proteins with hydrophobic domains and the DNAs which encode them
XX are useful for treating autoimmune disorders, burns and tumors and for
XX screening novel pharmaceuticals.
XX
XX Claim 1; Page 412-413; 518pp; English.
XX
XX AAF94417 to AAF94516 encode the human proteins given in AAB88557 to
XX AAB88606 (I) which have a hydrophobic domain. (I) have immunosuppressant,
XX anti-HIV, neuroprotective, antianaemic, vulnary, antiulcer,
XX osteopathic, anti-inflammatory and cytostatic activities, and can be used
XX in gene therapy. (I) can be used as pharmaceuticals and as antigens to
XX prepare antibodies. DNA and cDNA (II) encoding (I) can be used as probes
XX for genetic diagnosis and gene sources for gene therapy or for producing
XX (I) in large quantities. Cells containing (II) are used for the detection
XX of ligands or receptors corresponding to membrane or secretory proteins
XX and to screen small molecule novel pharmaceuticals. Antibodies directed
XX to (I) can be used for the detection, quantification and purification of
XX (I). Activities of (I) may include cytokine and cell
XX proliferation/differentiation function, immune stimulating or suppressing
XX activity, haematopoiesis regulating activity, tissue growth activity,
XX and chromobolytic activity, receptor/ligand activity and anti-inflammatory
XX activity. (I) and (II) can be used to treat autoimmune disorders e.g.
XX multiple sclerosis, HIV infections, anaemia, burns, ulcers, osteoporosis,
XX inflammatory bowel disease and tumours. (I) and (II) can also be used for
XX wound healing, as nutritional sources or supplements e.g. as amino acid,
XX carbon or nitrogen source, to effect metabolism, catabolism, anabolism,
XX processing and utilisation of dietary fat, protein, carbohydrate,
XX vitamins and minerals, to effect behavioural characteristics, to affect
XX appetite, and can act as antigens in vaccines to raise an immune response
XX to the protein or another material cross-reactive with the protein
XX
XX Sequence 227 AA;
Query Match 97.8%; Score 1177; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
DB 1 MGWTRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKV 60
QY 61 VPDCCNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
DB 61 VPDCCNNYRKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAEPRQFRWHLVTDIKG 120
QY 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPQFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGQELSAYQAPSPAHSGFHRYPQFVYLQEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFTMTQYQDSPTLQAPRGRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFTMTQYQDSPTLQAPRGRASEPKHKTR 221

```

QY 61 VPDCNNYRQKITSWMEPIVKFFPGAVDGYILVMVDPDAPSRAPRQRFWRHNLVTDIKG 120

Db 1 DEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKVWPDCNNYRQKITS

QY 83 GAVDGTATVLMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIOGQELSAIYQAPSPP 142  
 DB 61 GAVDGTATVLMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIOGQELSAIYQAPSPP 120  
 QY 143 AHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRFLNRFHLGEPPEASTQFMNTQYQD 202  
 DB 121 AHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRFLNRFHLGEPPEASTQFMNTQYQD 180  
 QY 203 SPTLOAPRGRASEPKHKTRQ 223  
 DB 181 SPTLOAPRGRASEPKHKTRR 201

RESULT 11  
 ADI34901  
 ID ADI34901 standard; protein; 205 AA.  
 XX AC ADI34901;  
 XX DT 06-MAY-2004 (first entry)  
 DE Cardiovascular disorder plasma polypeptide (CPP) 10 mature protein.  
 KW CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;  
 KW cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;  
 KW cardiovascular disorder; coronary artery disease; human.  
 XX OS Homo sapiens.  
 XX FH Location/Qualifiers  
 FT Disulfide-bond 8..36  
 FT Disulfide-bond /note = disulphide bridge  
 FT Disulfide-bond 21..42  
 FT Disulfide-bond /note = disulphide bridge  
 XX WO2004005931-A1.  
 XX 15-JAN-2004.  
 XX 26-JUN-2003; 2003WO-EP006766.  
 XX 08-JUL-2002; 2002US-0394576P.  
 XX 07-JAN-2003; 2003US-0438664P.  
 XX (GENE-) GENEPROT INC.  
 XX Bougueleret L, Jeandenans C, Pardo B;  
 XX WPI; 2004-108914/11.  
 XX Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful  
 PT for useful for screening and/or diagnosis of, or predicting  
 PT cardiovascular disorder, or for identifying CPP modulator.  
 XX Claim 7; SEQ ID NO 2; 109pp; English.  
 XX Thye invention relates to isolated cardiovascular disorder plasma  
 CC polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides  
 CC derived from them. The CPP fragments are useful for screening and/or  
 CC diagnosis of, or predicting a cardiovascular disorder (e.g., coronary  
 CC artery disease (CAD)) in a subject. An anti-CPP antibody is useful for  
 CC treating cardiovascular disorders e.g., coronary artery disease, stroke,  
 CC atherosclerosis, hypertension, etc. The present sequence represents a  
 CC human CPP10 mature protein sequence.  
 XX Sequence 205 AA;  
 XX Query Match 88.4%; Score 1064; DB 1; Length 205;  
 XX Best Local Similarity 98.0%; Pred. NO. 0;  
 XX Matches 195; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
 QY 23 DEDENSPCAHEALLDIEDTLFCQGLEVFYPELGNICKVDPDNNYRKITSMWEPVVKFP 82  
 DB 1 DEDENSPCAHEALLDIEDTLFCQGLEVFYPELGNICKVDPDNNYRKITSMWEPVVKFP 60  
 QY 83 GAVDGTATVLMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIOGQELSAIYQAPSPP 142  
 DB 61 GAVDGTATVLMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIOGQELSAIYQAPSPP 120  
 QY 143 AHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRFLNRFHLGEPPEASTQFMNTQYQD 202  
 DB 121 AHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRFLNRFHLGEPPEASTQFMNTQYQD 180  
 QY 203 SPTLOAPRGRASEPKHKTR 221  
 DB 181 SPTLOAPRGRASEPKHKNQ 199

RESULT 12  
 ADH80692  
 ID ADH80692 standard; protein; 183 AA.  
 XX AC ADH80692;  
 XX DT 22-APR-2004 (first entry)  
 DE Human polypeptide #9.  
 KW Human; coagulation disorder; haemophilia; wound; stroke; thrombosis;  
 KW myocardial infarction; cancer; bone fracture; Alzheimer's disease;  
 KW Parkinson's disease; autoimmune disorder; food supplement; haemostatic;  
 KW vulnary; cerebroprotective; thrombolytic; anticoagulant; cardiant;  
 KW cytosatic; osteopathic; neuroprotective; nootropic; antiparkinsonian;  
 KW immunosuppressive.  
 XX OS Homo sapiens.  
 XX US2003232054-A1.  
 XX 18-DEC-2003.  
 XX 08-NOV-2002; 2002US-00291265.  
 XX 25-JAN-2000; 2000US-00491404.  
 XX 17-JUL-2000; 2000US-00617746.  
 XX 03-AUG-2000; 2000US-00631451.  
 XX 15-SEP-2000; 2000US-00663870.  
 XX 25-JAN-2001; 2001WO-US002823.  
 XX 03-AUG-2001; 2001US-00922279.  
 XX (TANG/) TANG Y T.  
 XX (LIUC/) LIU C.  
 XX (ASUN/) ASUNDI V.  
 XX (CHEN/) CHEN R.  
 XX (QIAN/) QIAN X B.  
 XX (WANG/) WANG Z W.  
 XX (WEHR/) WEHRMAN T.  
 XX (ZHAN/) ZHANG J.  
 XX (ZHOU/) ZHOU P.  
 XX (CAOY/) CAO Y.  
 XX (DRMA/) DRMANAC R T.  
 XX Tang YT, Liu C, Asundi V, Chen R, Qian XB, Wang ZW, Wehrman T;  
 XX Zhang J, Zhou P, Cao Y, Drmanac RT;  
 XX WPI; 2004-061257/06.  
 XX New polynucleotides and polypeptides useful for diagnosing, preventing or  
 PT treating diseases involving aberrant protein expression or activity, e.g.  
 PT hemophilia, wounds, stroke, thrombosis, cancer or autoimmune disorders.  
 XX Claim 20; SEQ ID NO 717; 85pp; English.  
 XX The invention relates to new isolated polynucleotides and polypeptides.  
 CC The sequences, compositions and methods of the invention are useful for  
 CC diagnosing, preventing or treating diseases involving aberrant protein

CC expression or biological activity, such as coagulation disorders (e.g.  
 CC haemophilia), wounds, stroke, thrombosis, myocardial infarction, cancer,  
 CC bone fractures, Alzheimer's disease, Parkinson's disease and autoimmune  
 CC disorders. The polynucleotides may be used as hybridisation probes, as  
 CC oligomers or primers, for polymerase chain reaction, for chromosome and  
 CC gene mapping, in the recombinant production of proteins and in generation  
 CC of antisense DNA or RNA. The polypeptides may be used in generating  
 CC antibodies, as molecular weight markers or as food supplements. This  
 CC sequence represents a human polypeptide of the invention.  
 XX  
 SQ Sequence 183 AA;

Query Match 61.8%; Score 743.5; DB 1; Length 183;  
 Best Local Similarity 81.2%; Pred. No. 0;  
 Matches 147; Conservative 5; Mismatches 22; Indels 7; Gaps 3;  
 QY 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
 DB 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60  
 QY 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHVLVTDIKG 120  
 DB 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHVLVTDIKG 120  
 QY 121 ADLKGKIQGQELSAYQAPSPAH--SGFHRYPFVYLQEGKVISLLPKENKTR---GS 174  
 DB 121 ADLKGKIQGQELSALPGSLPHRTVAFLIRYQ-VLCLSGREGKSSLSFPKRTKLEALGK 179  
 QY 175 W 175  
 DB 180 W 180

RESULT 13  
 AAY11860  
 ID AAY11860 standard; protein; 121 AA.

XX AC AAY11860;

XX DT 18-JUN-1999 (first entry)

XX DE Human 5' EST secreted protein SEQ ID No: 460.

XX KW Human; secreted protein; EST; expressed sequence tag; diagnosis;  
 KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;  
 KW upstream regulatory sequence; cytokine activity; cell proliferation;  
 KW differentiation; haematopoiesis regulation; tissue growth regulation;  
 KW reproductiv hormone regulation; chemotactic; chemokinetic; haemostatic;  
 KW thrombolytic; anti-inflammatory; tumour inhibition.

XX OS Homo sapiens.

XX PN WO9906550-A2.

XX PD 11-FEB-1999.

XX PF 31-JUL-1998; 98WO-IB001232.

XX PR 01-AUG-1997; 97US-00905144.

XX FA (GEST ) GENSET.

XX FI Dumas Milne Edwards J, Duclert A, Lacroix B;

XX DR WPI; 1999-153780/13.

XX DR N-PSDB; AAX40582.

XX PT New isolated prostate-derived nucleic acids - used to develop products  
 PT which may have cytokine, immune regulatory, haematopoiesis regulating,  
 PT anti-inflammatory or tumour inhibition activity.

XX PS Claim 34; Page 589; 675pp; English.

CC AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for  
 CC human secreted proteins expressed in prostate, and encode the proteins  
 CC given in AAY11716 to AAY11993 respectively. The proteins given represent  
 CC the signal peptide and an N-terminal fragment of a secreted protein. The  
 CC nucleic acid sequences can be used for producing secreted human gene  
 CC products. They can also be used to develop products for diagnosis and  
 CC therapy. The proteins obtained may have cytokine activity, cell  
 CC proliferation and differentiation activity, haematopoiesis regulating  
 CC activity, tissue growth regulating activity, reproductiv hormone  
 CC regulating activity, chemotactic/chemokinetic activity, haemostatic and  
 CC thrombolytic activity, receptor/ligand activity, anti-inflammatory  
 CC activity, tumour inhibition activity or other activities. The products  
 CC can be used in forensic, gene therapy and chromosome mapping procedures.  
 CC The sequences can also be used for obtaining corresponding promoter  
 CC sequences. The nucleic acids encoding the signal peptides can be used for  
 CC directing extracellular secretion of a polypeptide or the insertion of a  
 CC polypeptide into a membrane, or importing a polypeptide into a cell  
 XX  
 SQ Sequence 121 AA;

Query Match 54.2%; Score 652; DB 1; Length 121;  
 Best Local Similarity 99.2%; Pred. No. 0;  
 Matches 120; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60

DB 1 MGWTMLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYPYELGNIGCKV 60

QY 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHVLVTDIKG 120

DB 61 VPDCNNYRQKITSWMEPIVKFPGAVDGTATYILVMVDPDAPSRAPRQRFWRHVLVTDIKG 120

QY 121 A 121

DB 121 A 121

Search completed: February 22, 2005, 12:54:10  
 Job time : 0.001 secs

RESULT 1	
ADI34902	
ID	ADI34902 standard; protein; 223 AA.
XX	
AC	ADI34902;
XX	
DT	06-MAY-2004 (first entry)
XX	
DE	Cardiovascular disorder plasma polypeptide (CPP) 11 precursor sequence.
XX	
KW	CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;
KW	cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;
KW	cardiovascular disorder; coronary artery disease; human.
XX	
OS	Homo sapiens.
XX	
FH	Key Location/Qualifiers







CC to identify individuals or in diagnostic procedures to identify  
CC individuals having genetic diseases resulting from abnormal expression of  
CC the genes corresponding to the extended cDNAs. They are also useful for  
CC constructing a high resolution map of the human chromosomes. They can  
CC also be used for gene therapy to control or treat genetic diseases  
XX  
SQ Sequence 227 AA;  
Query Match 97.8%; Score 1177; DB 1; Length 227;  
Best Local Similarity 98.6%; Pred. No. 0;  
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
QY 1 MGMTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
DB 1 MGMTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGAATYILVMVDPDAPSPRAEPRQRFWRHLVTDIKG 120  
DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGAATYILVMVDPDAPSPRAEPRQRFWRHLVTDIKG 120  
QY 121 ADLKGKIKQOELSAVQAPSPPAHSGFHRYPFVYLOEGKVISLPPKENTKTRGSKWMDRF 180  
DB 121 ADLKGKIKQOELSAVQAPSPPAHSGFHRYPFVYLOEGKVISLPPKENTKTRGSKWMDRF 180  
QY 181 LNRFLHGEPEASTQFMTQNTQYQDSPTLQAPRASEPKHKTR 221  
DB 181 LNRFLHGEPEASTQFMTQNTQYQDSPTLQAPRASEPKHKQ 221  
RESULT 6  
AAV64647  
ID AAY64647 standard; protein; 227 AA.  
AC AAY64647;  
XX  
XX 01-FEB-2000 (first entry)  
XX Human phosphatidylethanolamine-binding protein.  
XX  
XX Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;  
KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;  
KW location; development; protein synthesis; stability; regulation;  
KW identification.  
XX  
XX Homo sapiens.  
XX  
XX WO9953051-A2.  
XX  
XX 21-OCT-1999.  
XX  
XX 09-APR-1999; 99WO-IB000712.  
XX  
XX 09-APR-1998; 98US-00057719.  
PR 28-APR-1998; 98US-00069047.  
XX  
XX (GEST ) GENSET.  
XX  
XX Dumas Milne Edwards J, Duclert A, Giordano J;  
PI  
XX WPI; 2000-038446/03.  
DR N-PSDB; AA242252.  
XX  
XX Novel secreted protein 5', expressed sequence tag sequences used in  
PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.  
XX  
XX Example 21; Page 169-170; 837pp; English.  
XX  
XX AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)  
CC sequences, corresponding to human secreted proteins. AAY64651 to AAY65438  
CC represent the EST-related proteins corresponding to AA242265 to AA243052.  
CC The 5' ESTs can be used for producing secreted human gene products. They  
CC can be used to identify and isolate 5' untranslated regions (UTRs) and  
CC upstream regulatory regions which control the location, development

CC stage, rate, and quantity of protein synthesis, as well as stability of  
CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to  
CC obtain full length cDNA clones. The ESTs can also be used in forensic  
CC procedures to identify individuals, or in diagnostic procedures to  
CC identify individuals having genetic diseases resulting from abnormal gene  
CC expression. The products may also be used in gene therapy protocols. The  
CC nucleic acids encoding signal peptides can be used for directing  
CC extracellular secretion of a polypeptide or the insertion of a  
CC polypeptide into a membrane, or importing a polypeptide into a cell. The  
CC proteins encoded by the EST sequences may be useful in treating a variety  
CC of human conditions. Secreted proteins have therapeutic value, and the  
CC identification of new secreted proteins is valuable. AA242249 to AA242264  
CC and AAY64644 to AAY64650 represent sequences used in the exemplification  
CC of the present invention  
XX  
SQ Sequence 227 AA;  
Query Match 97.8%; Score 1177; DB 1; Length 227;  
Best Local Similarity 98.6%; Pred. No. 0;  
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
QY 1 MGMTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
DB 1 MGMTMLVTAALLGLMMVVTGDEENSPCAHEALLDEDTLFCQGLEVFYFPELGNIGCKV 60  
QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGAATYILVMVDPDAPSPRAEPRQRFWRHLVTDIKG 120  
DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGAATYILVMVDPDAPSPRAEPRQRFWRHLVTDIKG 120  
QY 121 ADLKGKIKQOELSAVQAPSPPAHSGFHRYPFVYLOEGKVISLPPKENTKTRGSKWMDRF 180  
DB 121 ADLKGKIKQOELSAVQAPSPPAHSGFHRYPFVYLOEGKVISLPPKENTKTRGSKWMDRF 180  
QY 181 LNRFLHGEPEASTQFMTQNTQYQDSPTLQAPRASEPKHKTR 221  
DB 181 LNRFLHGEPEASTQFMTQNTQYQDSPTLQAPRASEPKHKQ 221  
RESULT 7  
AAB88590  
ID AAB88590 standard; protein; 227 AA.  
AC AAB88590;  
XX  
XX 04-JUN-2001 (first entry)  
XX Human hydrophobic domain containing protein clone HP03880 #94.  
XX  
XX Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;  
KW antianemic; vulnery; antiulcer; osteopathic; anti-inflammatory;  
KW cytostatic; gene therapy; autoimmune disorder; multiple sclerosis;  
KW HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;  
KW inflammatory bowel disease; nutritional supplement; appetite; vaccine;  
KW behavioural characteristic; immune response.  
XX  
XX Homo sapiens.  
XX  
XX WO200112660-A2.  
XX  
XX 22-FEB-2001.  
XX  
XX 10-AUG-2000; 2000WO-JP0053356.  
XX  
XX 17-AUG-1999; 99JP-00210344.  
PR 07-SEP-1999; 99JP-00252551.  
PR 01-OCT-1999; 99JP-00281132.  
PR 22-OCT-1999; 99JP-00301624.  
PR 04-NOV-1999; 99JP-00313877.  
XX  
XX (SAGA ) SAGAMI CHEM RES CENT.  
PA (PROT-) PROTEGENE INC.  
XX  
XX Kato S, Kimura T; PI



```

XX WPI: 2001-160059/16.
DR N-PSDB; AAF94480.
XX
PT Human proteins with hydrophobic domains and the DNAs which encode them
PT are useful for treating autoimmune disorders, burns and tumors and for
PT screening novel pharmaceuticals.
XX
XX Claim 1; Page 412-413; 518pp; English.
XX
PS AAF94417 to AAF94516 encode the human proteins given in AAB88557 to
CC AAB88606 (I) which have a hydrophobic domain. (I) have immunosuppressant,
CC anti-HIV, neuroprotective, antianaemic, vulnerary, antitumor,
CC osteopathic, anti-inflammatory and cytostatic activities, and can be used
CC in gene therapy. (I) can be used as pharmaceuticals and as antigens to
CC prepare antibodies. DNA and cDNA (II) encoding (I) can be used as probes
CC for genetic diagnosis and gene sources for gene therapy or for producing
CC (I) in large quantities. Cells containing (I) are used for the detection
CC of ligands or receptors corresponding to membrane or secretory proteins
CC and to screen small molecule novel pharmaceuticals. Antibodies directed
CC to (I) can be used for the detection, quantification and purification of
CC (I). Activities of (I) may include cytokine and cell
CC proliferation/differentiation function, immune stimulating or suppressing
CC activity, haematopoiesis regulating activity, tissue growth activity,
CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, receptor/ligand activity and anti-inflammatory
CC activity. (I) and (II) can be used to treat autoimmune disorders e.g.
CC multiple sclerosis, HIV infections, anaemia, burns, ulcers, osteoporosis,
CC inflammatory bowel disease and tumours. (I) and (II) can also be used for
CC wound healing, as nutritional sources or supplements e.g. as amino acid,
CC carbon or nitrogen source, to effect metabolism, catabolism, anabolism,
CC processing and utilisation of dietary fat, protein, carbohydrate,
CC vitamins and minerals, to effect behavioural characteristics, to affect
CC appetite, and can act as antigens in vaccines to raise an immune response
CC to the protein or another material cross-reactive with the protein
XX
XX Sequence 227 AA;
XX
Query Match 97.8%; Score 1177; DB 1; Length 227;
Best Local Similarity 98.6%; Pred. No. 0;
Matches 218; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 1 MGWTMRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60
DB 1 MGWTMRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60
QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120
DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120
QY 121 ADLKGKIQGQELSAYQAPSPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGQELSAYQAPSPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRASEPKHKQ 221
RESULT 8
AD134900
ID AD134900 standard; protein; 227 AA.
XX
XX AD134900;
XX
XX 06-MAY-2004 (first entry)
XX
DE Cardiovascular disorder plasma polypeptide (CPP) 10 precursor sequence.
XX
XX CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;
XX
XX cardiac; cerebroprotective; antiarteriosclerotic; hypotensive;
XX
XX cardiovascular disorder; coronary artery disease; human.
XX

```

---

```

OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX Peptide 1..22
XX Protein /note= "signal peptide"
XX /note= "mature protein"
XX Disulfide-bond 30..58
XX /note= disulphide bridge
XX Disulfide-bond 43..64
XX /note= disulphide bridge
XX
XX WO2004005931-A1.
XX
XX 15-JAN-2004.
XX
XX 26-JUN-2003; 2003WO-EP006766.
XX
XX 08-JUL-2002; 2002US-0394576P.
XX 07-JAN-2003; 2003US-0438664P.
XX (GENE-) GENEPROT INC.
XX
XX Bougueleret L, Jeandenans C, Pardo B;
XX
XX WPI: 2004-108914/11.
XX SWISSPROT; Q96S96.
XX
XX Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful
XX for useful for screening and/or diagnosis of, or predicting
XX cardiovascular disorder, or for identifying CPP modulator.
XX
XX Claim 7; SEQ ID NO 1; 109pp; English.
XX
XX Thye invention relates to isolated cardiovascular disorder plasma
XX polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides
XX derived from them. The CPP fragments are useful for screening and/or
XX diagnosis of, or predicting a cardiovascular disorder (e.g., coronary
XX artery disease (CAD)) in a subject. An anti-CPP antibody is useful for
XX treating cardiovascular disorders e.g., coronary artery disease, stroke,
XX atherosclerosis, hypertension, etc. The present sequence represents a
XX human CPP10 precursor protein sequence.
XX
XX Sequence 227 AA;
XX
Query Match 97.4%; Score 1173; DB 1; Length 227;
Best Local Similarity 98.2%; Pred. No. 0;
Matches 217; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 1 MGWTMRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60
DB 1 MGWTMRLVTAALLGLMMVVTGDEDENSPCAHEALLDEDTLFCQGLEVFYFELGNIGCKV 60
QY 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120
DB 61 VPDCCNNYRQKITSWMEPIVKFPGAVDGYATILVMVDPDAPRAEPQRQFWRHVLVTDIKG 120
QY 121 ADLKGKIQGQELSAYQAPSPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180
DB 121 ADLKGKIQGQELSAYQAPSPAHSGFHYQFFVYLQEGKVISLLPKENKTRGSKWMDRF 180
QY 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRASEPKHKTR 221
DB 181 LNRFLHGEPEASTQFMNTQYQDSPTLQAPRASEPKHKQ 221
RESULT 9
AD134903
ID AD134903 standard; protein; 201 AA.
XX
XX AD134903;
XX
XX 06-MAY-2004 (first entry)
XX

```

XX	Cardiovascular disorder plasma polypeptide (CPP) 11 mature protein.
DE	CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;
XX	cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;
KW	cardiovascular disorder; coronary artery disease; human.
KW	Homo sapiens.
OS	
XX	Key
PH	Location/Qualifiers
FT	Disulfide-bond 8..36
FT	/note = disulphide bridge
FT	Disulfide-bond 21..42
FT	/note = disulphide bridge
XX	WO2004005931-A1.
XX	15-JAN-2004.
XX	26-JUN-2003; 2003WO-EP006766.
XX	08-JUL-2002; 2002US-0394576P.
PR	07-JAN-2003; 2003US-0438664P.
XX	(GENE-) GENEPROT INC.
PA	
XX	Bougueleret L, Jeandenans C, Pardo B;
PI	WPI; 2004-108914/11.
XX	Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful
PT	for useful for screening and/or diagnosis of, or predicting
PT	cardiovascular disorder, or for identifying CPP modulator.
PT	
XX	Claim 7; SEQ ID NO 4; 109pp; English.
PS	
XX	Thye invention relates to isolated cardiovascular disorder plasma
CC	polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides
CC	derived from them. The CPP fragments are useful for screening and/or
CC	diagnosis of, or predicting a cardiovascular disorder (e.g., coronary
CC	artery disease (CAD)) in a subject. An anti-CPP antibody is useful for
CC	treatment of cardiovascular disorders e.g., coronary artery disease, stroke,
CC	atherosclerosis, hypertension, etc. The present sequence represents a
CC	human CPP11 mature protein sequence.
XX	
SQ	Sequence 201 AA;
Query Match 90.3%; Score 1087; DB 1; Length 201;	
Best Local Similarity 99.0%; Pred. No. 0;	
Matches 199; Conservative 2; Mismatches 0; Indels 0; Gaps 0;	
QY	23 DEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKVVDPCNNYRQKITSWMEPIVKFP 82
DB	1 DEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKVVDPCNNYRQKITSWMEPIVKFP 60
QY	83 GAVDGTATYLLVMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIQGQELSAQAPSPP 142
DB	61 GAVDGTATYLLVMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIQGQELSAQAPSPP 120
QY	143 AHSGFHYRQFFVYLOEGKVISLIPKENTRGSKWMDRFLNRFHLGEPASTQFTQNYQD 202
DB	121 AHSGFHYRQFFVYLOEGKVISLIPKENTRGSKWMDRFLNRFHLGEPASTQFTQNYQD 180
QY	203 SPTLOAPRGRASEPKHKTRR 223
DB	181 SPTLOAPRGRASEPKHKTRR 201
RESULT 10	
ADI34901	
ADI34901 standard; protein; 205 AA.	
XX	
AC	ADI34901;

XX	06-MAY-2004 (first entry)
DE	Cardiovascular disorder plasma polypeptide (CPP) 10 mature protein.
XX	CPP; CPP10; CPP11; CAD; cardiovascular disorder plasma polypeptide;
KW	cardiant; cerebroprotective; antiarteriosclerotic; hypotensive;
KW	cardiovascular disorder; coronary artery disease; human.
OS	Homo sapiens.
XX	Key
PH	Location/Qualifiers
FT	Disulfide-bond 8..36
FT	/note = disulphide bridge
FT	Disulfide-bond 21..42
FT	/note = disulphide bridge
XX	WO2004005931-A1.
XX	15-JAN-2004.
XX	26-JUN-2003; 2003WO-EP006766.
XX	08-JUL-2002; 2002US-0394576P.
PR	07-JAN-2003; 2003US-0438664P.
XX	(GENE-) GENEPROT INC.
PA	
XX	Bougueleret L, Jeandenans C, Pardo B;
PI	WPI; 2004-108914/11.
XX	Novel isolated cardiovascular disorder plasma polypeptide (CPP) useful
PT	for useful for screening and/or diagnosis of, or predicting
PT	cardiovascular disorder, or for identifying CPP modulator.
PT	
XX	Claim 7; SEQ ID NO 2; 109pp; English.
PS	
XX	Thye invention relates to isolated cardiovascular disorder plasma
CC	polypeptide (CPP), especially CPP10 and CPP11 and tryptic peptides
CC	derived from them. The CPP fragments are useful for screening and/or
CC	diagnosis of, or predicting a cardiovascular disorder (e.g., coronary
CC	artery disease (CAD)) in a subject. An anti-CPP antibody is useful for
CC	treatment of cardiovascular disorders e.g., coronary artery disease, stroke,
CC	atherosclerosis, hypertension, etc. The present sequence represents a
CC	human CPP10 mature protein sequence.
XX	
SQ	Sequence 205 AA;
Query Match 88.4%; Score 1064; DB 1; Length 205;	
Best Local Similarity 98.0%; Pred. No. 0;	
Matches 195; Conservative 2; Mismatches 2; Indels 0; Gaps 0;	
QY	23 DEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKVVDPCNNYRQKITSWMEPIVKFP 82
DB	1 DEDENSPCAHEALLDEDTLFCQGLEVFYPELGNIGCKVVDPCNNYRQKITSWMEPIVKFP 60
QY	83 GAVDGTATYLLVMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIQGQELSAQAPSPP 142
DB	61 GAVDGTATYLLVMVDPDAPSRAEPRQRFWRHVLVTDIKGADLKKGKIQGQELSAQAPSPP 120
QY	143 AHSGFHYRQFFVYLOEGKVISLIPKENTRGSKWMDRFLNRFHLGEPASTQFTQNYQD 202
DB	121 AHSGFHYRQFFVYLOEGKVISLIPKENTRGSKWMDRFLNRFHLGEPASTQFTQNYQD 180
QY	203 SPTLOAPRGRASEPKHKTR 221
DB	181 SPTLOAPRGRASEPKHKTR 199
RESULT 11	
AAY11860	
ID AAY11860 standard; protein; 121 AA.	

Search completed: February 22, 2005, 14:26:21  
Job time : 1 secs

```

XX AAY11860;
AC
XX 18-JUN-1999 (first entry)
DT
XX
XX Human 5' EST secreted protein SEQ ID No: 460.
DE
XX
XX Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW upstream regulatory sequence; cytokine activity; cell proliferation;
KW differentiation; haematopoiesis regulation; tissue growth regulation;
KW reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS Homo sapiens.
XX
XX WO9906550-A2.
FN
XX
XX 11-FEB-1999.
PD
XX
XX 31-JUL-1998; 98WO-IB001232.
PF
XX
XX 01-AUG-1997; 97US-00905144.
PR
XX
XX (GEST ) GENSET.
PA
XX
XX Dumas Milne Edwards J, Duclert A, Lacroix B;
PI
XX
XX WPI; 1999-153780/13.
DR
XX N-PSDB; AAX40582.
XX
XX New isolated prostate-derived nucleic acids - used to develop products
PT which may have cytokine, immune regulatory, haematopoiesis regulating,
PT anti-inflammatory or tumour inhibition activity.
XX
XX Claim 34; Page 589; 675pp; English.
PS
XX
XX AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
CC human secreted proteins expressed in prostate, and encode the proteins
CC given in AAY11716 to AAY11993 respectively. The proteins given represent
CC the signal peptide and an N-terminal fragment of a secreted protein. The
CC nucleic acid sequences can be used for producing secreted human gene
CC products. They can also be used to develop products for diagnosis and
CC therapy. The proteins obtained may have cytokine activity, cell
CC proliferation and differentiation activity, haematopoiesis regulating
CC activity, tissue growth regulating activity, reproductive hormone
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity, tumour inhibition activity or other activities. The products
CC can be used in forensic, gene therapy and chromosome mapping procedures.
CC The sequences can also be used for obtaining corresponding promoter
CC sequences. The nucleic acids encoding the signal peptides can be used for
CC directing extracellular secretion of a polypeptide or the insertion of a
CC polypeptide into a membrane, or importing a polypeptide into a cell
XX
XX Sequence 121 AA;
SQ
Query Match 54.2%; Score 652; DB 1; Length 121;
Best Local Similarity 99.2%; Pred. No. 0;
Matches 120; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MCGWTRLVTAAALLGLMMVVTGDEDNSSPCAHEALLDEDTLFCQGLEVPYFPELGNIGCKV 60
DB 1 MCGWTRLVTAAALLGLMMVVTGDEDNSSPCAHEALLDEDTLFCQGLEVPYFPELGNIGCKV 60

QY 61 VPDCCNYROKITSWNEPIVKFPFGAVDGATYILVMVDPDAPSRAEPRQRFWRHVLVDIKG 120
DB 61 VPDCCNYROKITSWNEPIVKFPFGAVDGATYILVMVDPDAPSRAEPRQRFWRHVLVDIKG 120

QY 121 A 121
DB 121 A 121

```

